Erlotinib Versus Oral Etoposide in Patients With Recurrent or Refractory Pediatric Ependymoma
Status:
Terminated
Trial end date:
2012-11-26
Target enrollment:
Participant gender:
Summary
This is a phase 2 study to evaluate the efficacy of single-agent erlotinib versus oral
etoposide in patients with recurrent or refractory pediatric ependymoma.